Saturday, 27th of July 2013 |
Bull World Health Organ. 2012 Aug 1;90(8):623-8. doi: 10.2471/BLT.11.097253. Epub 2012 May 23.
Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F.
Source
Ministry of Health, Kigali, Rwanda.
Abstract below; full text, with figures, is at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417784/
PROBLEM:
Virtually all women who have cervical cancer are infected with the human papillomavirus (HPV). Of the 275,000 women who die from cervical cancer every year, 88% live in developing countries. Two vaccines against the HPV have been approved. However, vaccine implementation in low-income countries tends to lag behind implementation in high-income countries by 15 to 20 years.
APPROACH:
In 2011, Rwandas Ministry of Health partnered with Merck to offer the Gardasil HPV vaccine to all girls of appropriate age. The Ministry formed a "public-private community partnership" to ensure effective and equitable delivery.
LOCAL SETTING:
Thanks to a strong national focus on health systems strengthening, more than 90% of all Rwandan infants aged 12-23 months receive all basic immunizations recommended by the World Health Organization.
RELEVANT CHANGES:
In 2011, Rwandas HPV vaccination programme achieved 93.23% coverage after the first three-dose course of vaccination among girls in grade six. This was made possible through school-based vaccination and community involvement in identifying girls absent from or not enrolled in school. A nationwide sensitization campaign preceded delivery of the first dose.
LESSONS LEARNT:
Through a series of innovative partnerships, Rwanda reduced the historical two-decade gap in vaccine introduction between high- and low-income countries to just five years. High coverage rates were achieved due to a delivery strategy that built on Rwandas strong vaccination system and human resources framework. Following the GAVI Alliances decision to begin financing HPV vaccination, Rwandas example should motivate other countries to explore universal HPV vaccine coverage, although implementation must be tailored to the local context.
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
42371293 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |